![Lode Debrabandere](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Lode Debrabandere
Direktor/Vorstandsmitglied bei Prolexys Pharmaceuticals, Inc.
Aktive Positionen von Lode Debrabandere
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Prolexys Pharmaceuticals, Inc.
![]() Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | Direktor/Vorstandsmitglied | - | - |
Karriereverlauf von Lode Debrabandere
Ehemalige bekannte Positionen von Lode Debrabandere
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ELUTIA INC. | Direktor/Vorstandsmitglied | - | 04.06.2018 |
Vorstandsvorsitzender | - | 04.06.2018 | |
Präsident | - | 04.06.2018 | |
OSIRIS THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 01.07.2006 | 03.02.2016 |
Vorstandsvorsitzender | 02.12.2013 | 03.02.2016 | |
Geschäftsführer | 26.10.2012 | 01.11.2013 | |
Corporate Officer/Principal | 01.07.2006 | 26.10.2012 | |
Präsident | 02.12.2013 | 03.02.2016 | |
BRISTOL-MYERS SQUIBB COMPANY | Vertrieb & Marketing | - | - |
Ausbildung von Lode Debrabandere
Katholieke Universiteit Leuven | Doctorate Degree |
Statistik
International
Vereinigte Staaten | 5 |
Belgien | 2 |
Operativ
Director/Board Member | 3 |
Chief Executive Officer | 2 |
President | 2 |
Sektoral
Health Technology | 5 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
ELUTIA INC. | Health Technology |
Private Unternehmen | 2 |
---|---|
Osiris Therapeutics, Inc.
![]() Osiris Therapeutics, Inc. BiotechnologyHealth Technology Osiris Therapeutics, Inc. engages in the research, development, manufacture, and commercialization of regenerative medicine products. Its biosurgery business focuses on using unique tissue preservation technologies to develop viable human tissue products designed to improve wound closure and surgical outcomes for patients and physicians over standard of care alone. The company was founded by Peter A. Friedli and James S. Burns on December 23, 1992 and is headquartered in Columbia, MD. | Health Technology |
Prolexys Pharmaceuticals, Inc.
![]() Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | Health Technology |
- Börse
- Insiders
- Lode Debrabandere
- Erfahrung